test

SUNSHINE BIOPHARMA SIGNS EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF GEORGIA FOR COVID-19 COMPOUNDS

For Immediate Release February 4, 2021

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a  pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has signed an exclusive license agreement  with the University of Georgia (“UGA”) for two Anti-Coronavirus compounds which UGA had  previously developed and patented. Sunshine Biopharma and UGA will advance the development  of these two compounds in parallel with Sunshine Biopharma’s own SBFM-PL4. The next step in  the development plan involves testing of the efficacy of these compounds in transgenic mice.  Mice which have been genetically engineered to become susceptible to infection by SARS-CoV 

2, the causative agent of COVID-19, will be challenged with the virus and subsequently treated with the test compounds to determine if progression to diseases can be arrested. Such studies  are anticipated to be underway later this month. 

“We are delighted to have reached this agreement with the University of Georgia,” said Dr. Steve  N. Slilaty, CEO of Sunshine Biopharma. “UGA’s compounds expand our war chest and enhance  our effort to hone in on a most effective treatment for COVID-19,” he added. 

About Sunshine Biopharma’s COVID-19 Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the etiologic agent of  COVID-19, the current ongoing pandemic that has claimed the lives of over 2.2 million people  worldwide since it first appeared in December 2019. There are currently no drugs that can  effectively arrest replication of the virus in people who have contracted the illness. On May 22,  2020, Sunshine Biopharma filed a provisional patent application for a library of molecules which  were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to  multiply and cause illness. Sunshine Biopharma has since screened the library and identified a  lead Anti-Coronavirus compound (SBFM-PL4). The Company is currently conducting a series of  in vitro tests to evaluate its specific inhibitory activity of SBFM-PL4 against the SARS-CoV-2  papain-like protease (PLpro), one of two Coronavirus encoded proteases essential for viral  replication. Following the initial in vitro studies, SBFM-PL4 will be moved forward to the cell culture  testing stage and assessment in Coronavirus infected mice before entering human clinical trials. 

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date 

have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner  of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com